Using low-dose pioglitazone to improve health outcomes in patients with type 2 diabetes and liver disease.
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH
['FUNDING_R01'] · UNIVERSITY OF FLORIDA · NIH-10613936
This study is looking at how early check-ups and treatment can help people with type 2 diabetes who might also have a liver condition called NASH, and it will teach doctors about the benefits of spotting this issue early and using a medication called pioglitazone to help improve liver health.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF FLORIDA (nih funded) |
| Locations | 1 site (GAINESVILLE, UNITED STATES) |
| Trial ID | NIH-10613936 on ClinicalTrials.gov |
What this research studies
This research investigates the role of screening and early intervention in primary care for patients with type 2 diabetes mellitus (T2DM) who may also have nonalcoholic steatohepatitis (NASH). It aims to educate primary care physicians about the risks associated with NASH and the importance of systematic screening. The study will explore the effects of low-dose pioglitazone, a medication that has shown promise in resolving NASH in a significant percentage of patients, while addressing concerns about its side effects. By identifying and treating patients earlier, the research seeks to improve overall health outcomes and reduce the risk of severe liver complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 2 diabetes mellitus who may also be at risk for nonalcoholic steatohepatitis.
Not a fit: Patients who do not have type 2 diabetes or those with advanced liver disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier diagnosis and treatment of NASH in patients with T2DM, potentially preventing severe liver disease and improving patient quality of life.
How similar studies have performed: Previous studies have indicated that low-dose pioglitazone can effectively resolve NASH in a substantial number of patients, suggesting that this approach has potential for success.
Where this research is happening
GAINESVILLE, UNITED STATES
- UNIVERSITY OF FLORIDA — GAINESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CUSI, KENNETH — UNIVERSITY OF FLORIDA
- Study coordinator: CUSI, KENNETH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bladder Cancer, Urinary Bladder Cancer, Cardiovascular Diseases, cardiovascular disorder